Opportunity timeline

PostedJun 15, 2026
DeadlineDec 16, 2026

In plain English

Los Alamos National Laboratory is offering licensing for DC Recruiter, a self-assembling peptide nanofiber designed to recruit and activate dendritic cells for broad, early immune support against infections. The concept is needle-free and spray-friendly, with potential uses in outbreak response, defense, emergency preparedness, pharmaceuticals and consumer health. The technology is at TRL 3, has a US patent pending, and is available through exclusive or non-exclusive licensing agreements; this is not a request for development services.

About this opportunity

DC Recruiter: Broad-Spectrum Immune Enhancer from scientists at Los Alamos National Laboratory offers a differentiated approach to multi-pathogen infection prevention by using a self-assembling peptide nanofiber to recruit and activate dendritic cells (DCs), the immune system’s natural sentinels. Unlike pathogen-specific vaccines or therapeutics, it is designed to help trigger an early immune response regardless of the infecting agent. Its needle-free, spray-friendly concept adds practicality. The Challenge: DC Recruiter addresses a persistent and highly consequential gap in infection management: the need for a rapid, broadly effective way to stimulate immune defense before the specific…

Time remaining

Closes Dec 16, 2026

92Days
:
16Hours
:
09Min
:
16Sec

Related Opportunities

Bid details are gathered and summarized automatically. Please verify details at the original source.

Ref No.

BS-CCA5D7